Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-038 in relapsed/refractory NHL and ALL
NCT04606433Phase 1Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Dec 2025
- Modality
- Multispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emfizatamab in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 14 days, Maximum Tolerated Dose at 14 days and 3 more. Started Nov 2020; status: active, not recruiting.
02
Drugs
emfizatamab
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04606433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606433.